Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.41 |
| ▸ | CNR2 | P34972 | 8/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | PPID | Q08752 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3190487 | 0.90 | CNR1 (0.41) | CNR1CNR2RAB9APOLBLMNA | |
| SCHEMBL3180971 | 0.88 | CNR1 (0.43) | CNR1CNR2RAB9APOLBLMNA | |
| SCHEMBL3187288 | 0.87 | PPID (0.46) | CNR1CNR2RAB9AL3MBTL1POLB | |
| SCHEMBL3187490 | 0.86 | POLB (0.39) | CNR1CNR2RAB9APOLBLMNA | |
| SCHEMBL3180943 | 0.83 | MAPT (0.44) | CNR1CNR2RAB9APOLBTP53 | |
| SCHEMBL3199031 | 0.82 | ALDH1A1 (0.43) | CNR1CNR2RAB9APOLBLMNA | |
| SCHEMBL3189090 | 0.82 | ALDH1A1 (0.39) | CNR1CNR2RAB9APOLBLMNA | |
| SCHEMBL13255046 | 0.82 | RAB9A (0.40) | CNR1CNR2RAB9APOLBLMNA | |
| SCHEMBL3191831 | 0.82 | GFER (0.39) | CNR1CNR2RAB9APOLBLMNA | |
| SCHEMBL3189116 | 0.82 | RAB9A (0.45) | CNR1CNR2RAB9AL3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168108-A1 | PHENYL DERIVATIVES AND METHODS OF USE | ADOLOR CORPORATION (US) | 2010-07-01 | — | — | US | claimed |
| US-20060074086-A1 | Phenyl derivatives and methods of use | ADOLOR CORPORATION (US) | 2006-04-06 | — | — | US | claimed |
| US-20100168108-A1 | PHENYL DERIVATIVES AND METHODS OF USE | ADOLOR CORPORATION (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100168108-A1 | PHENYL DERIVATIVES AND METHODS OF USE | ADOLOR CORPORATION (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100168108-A1 | PHENYL DERIVATIVES AND METHODS OF USE | ADOLOR CORPORATION (US) | 2010-07-01 | — | — | US | disclosed |
| US-7671052-B2 | Phenyl derivatives and methods of use | ADOLOR CORPORATION (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671052-B2 | Phenyl derivatives and methods of use | ADOLOR CORPORATION (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671052-B2 | Phenyl derivatives and methods of use | ADOLOR CORPORATION (US) | 2010-03-02 | — | — | US | disclosed |
| US-20060074086-A1 | Phenyl derivatives and methods of use | ADOLOR CORPORATION (US) | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074086-A1 | Phenyl derivatives and methods of use | CNR2, CNR1, GPR119 | CNR1 2/4885CNR2 1/4885RAB9A 2079/4885 |
| US-20100168108-A1 | PHENYL DERIVATIVES AND METHODS OF USE | CNR2, CNR1, GPR119 | CNR1 2/4885CNR2 1/4885RAB9A 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.